New analyses from the Phase 2b trial (NCT03272347) evaluating the safety and efficacy of islatravir, US-based pharmaceutical company Merck's (NYSE: MRK) investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTRO), in adults with HIV-1 infection who had not previously received antiretroviral treatment, the company said.
The first sub-analysis further characterized the tolerability and safety profile of islatravir in combination with doravirine (100 mg) through Week 48 across the three dose levels studied (0.25, 0.75, 2.25 mg).
The second sub-analysis demonstrated that participants who initiated treatment with islatravir and doravirine in combination with 3TC and switched to islatravir and doravirine maintained antiviral activity at Week 48 as measured by HIV-1 RNA
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study
SparX Biopharmaceutical doses first subject with SPX-303 injection
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Gabather collaborates with Denmark's Centre for Neuropsychiatric Schizophrenia Research
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
4basebio supplies opDNA DNA products to Tier 1 Pharma client
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories